On April 21, the US Supreme Court rejected lower court decisions restricting or altogether banning abortion medication Mifepristone and, by extension, the regulatory power of the FDA. The case is now in the hands of the 5th Circuit Court of Appeals, which will begin hearing oral arguments on May 17.

For more details and responses, see the range of sources below.
NPR presents a timeline starting with Texas Judge Matthew Kacsmaryk’s order through yesterday’s response from the Supreme Court.

DemocracyNow! turns to law professor and reproductive justice Michelle Goodwin and abortion provider Julie Burkhart for analysis of Kacsmaryk’s suspension of Mifepristone and the state of abortion care in the US. See also Dr. Goodwin’s book, Policing the Womb: Invisible Women and the Criminalization of Motherhood and guest essay in The New York Times, along with Burkhart’s Salon article.

Meanwhile, Hannah Levintova at Mother Jones presents a long-form investigation of Mifeprex’s private equity investors who stand to profit from the pill’s protection. See also Madison Pauly’s analysis of the resurgence of the Comstock Act for Mother Jones.

Kiarash Aramesh writes for The Hastings Center’s Bioethics Forum that the struggle over Mifepristone and abortion care in the U.S. more generally indicates an accelerating slide into theocracy.

Reach out to the IJFABBlog editors with pitches for feminist bioethical analyses of the struggle for medication abortion.